Document Detail

Long term recombinant interferon alpha treatment in MS with special emphasis to side effects.
MedLine Citation:
PMID:  9345419     Owner:  NLM     Status:  MEDLINE    
Twenty relapsing-remitting (RR) clinically definite MS patients were treated with 9 MIU intramuscular recombinant interferon alpha-2a (rIFNA) (Roferon-A, Roche) (n = 12) or placebo (n = 8) every other day for 6 months and followed up for a further 6 months after stopping treatment. Numbers of active lesions at MRI and of patients with clinical-MRI signs of disease activity and lymphocyte interferon gamma production, which were decreased during treatment, returned to values similar to baseline and placebos after stopping treatment. rIFNA chronic therapy seems therefore needed in order to maintain drug efficacy. Side effect profile was monitored, too, for over 1 year in the same 20 patients plus 25 additional RR MS patients. Besides the typical side effects of type I interferon therapy (fever, fatigue, depression, lymphopenia, hepatic enzyme elevation), occurrence of serum autoAbs was noted in 30% patients (in 60% antinuclear and in 80% antithyroid autoAbs). In two patients rIFNA treatment was stopped, in one case for antithyroid autoAbs and hypothyroidism, in the other for antinuclear autoAbs and a five-fold increase of ALT. A careful monitoring of serum autoAbs and of signs of thyroid or liver damage must always precede and accompany longterm type I IFN therapy.
L Durelli; M R Bongioanni; B Ferrero; D Imperiale; E Verdun; A Oggero; E Gentile; G B Bradac; M Bergui; L Bergamini; B Bergamasco
Related Documents :
17956829 - Effect of adherence to haart on virologic outcome and on the selection of resistance-co...
12707419 - Interferon beta-1a as an investigational treatment for cidp.
17622789 - Clevudine therapy for 24 weeks further reduced serum hepatitis b virus dna levels and i...
23339639 - High-frequency oscillation in early acute respiratory distress syndrome.
11148569 - Primary central nervous system lymphoma 1991-1997: outcome and late adverse effects aft...
21834769 - Novel design and synthesis of modified structure of carvedilol.
17576969 - Adding ketamine to morphine for patient-controlled analgesia after thoracic surgery: in...
23720509 - Patient reported outcome measures in military patients with shoulder instability.
6360749 - Efficacy and safety of a non-acetylated salicylate, choline magnesium trisalicylate, in...
Publication Detail:
Type:  Clinical Trial; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Multiple sclerosis (Houndmills, Basingstoke, England)     Volume:  1     ISSN:  1352-4585     ISO Abbreviation:  Mult. Scler.     Publication Date:  1996 Jul 
Date Detail:
Created Date:  1997-12-12     Completed Date:  1997-12-12     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  9509185     Medline TA:  Mult Scler     Country:  ENGLAND    
Other Details:
Languages:  eng     Pagination:  366-71     Citation Subset:  IM    
Clinica delle Malattie del Sistema Nervoso, Universita di Torino, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Autoantibodies / immunology
Follow-Up Studies
Interferon Type I, Recombinant / adverse effects,  therapeutic use*
Magnetic Resonance Imaging
Multiple Sclerosis / drug therapy*,  immunology
Pilot Projects
Reg. No./Substance:
0/Autoantibodies; 0/Interferon Type I, Recombinant

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  CAMPATH-IH in multiple sclerosis.
Next Document:  Treatment of relapsing-remittent multiple sclerosis with recombinant human interferon-alfa-2a: desig...